Drugs / monoclonal antibody to TGF-beta
monoclonal antibody to TGF-beta
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01291784 | Feb 2011 → Jan 2013 | myelofibrosis, primary myelofibrosis | John Mascarenhas | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | monoclonal antibody to TGF-beta | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01291784 ↗ |
| Action | Inhibit | “inhibiting the TGF-β signaling pathway” NCT01291784 ↗ |
| Modality | Monoclonal antibody | “monoclonal antibody to TGF-beta” NCT01291784 ↗ |
| Route | Intravenous | “intravenous” NCT01291784 ↗ |